Overview

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of irinotecan liposome injection combined with 5-FU/LV in the treatment of advanced neuroendocrine carcinoma (NEC)
Phase:
PHASE4
Details
Lead Sponsor:
Beijing GoBroad Hospital
Collaborator:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Fluorouracil